other

Parkin (Phospho-Ser131) Antibody

MBS8509495

0.1 mg

280 USD

Antibody

Parkin (Phospho-Ser131) Antibody

[Parkin]

[EC 6.3.2.-; PARK2; PRKN2; Parkinson disease protein 2; Parkinson juvenile disease protein 2; ubiquitin E3 ligase PRKN]

[E3 ubiquitin-protein ligase parkin isoform 1; E3 ubiquitin-protein ligase parkin; E3 ubiquitin-protein ligase parkin; parkin RBR E3 ubiquitin protein ligase; Parkin RBR E3 ubiquitin-protein ligase]

[PRKN]

[PRKN; PRKN; PDJ; AR-JP; LPRS2; PARK2; Parkinson disease protein 2]

Human, Mouse

465

Parkin (Phospho-Ser131) antibody detects endogenous levels of Parkin only when phosphorylated at serine 131.

Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.

In phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Store at-20 degree C for 1 year.

Immunohistochemistry (IHC), ELISA (EIA)

IHC: 1:50-1:100. ELISA: 1:10000

Immunohistochemistry (IHC)

Immunogen: The antiserum was produced against synthesized phosphopeptide derived from human Parkin around the phosphorylation site of serine 131 (K-D-SP-P-P).

All Sites: Human: Ser131. Mouse: Ser131

J. Menéndez, Hum. Mol. Genet., Jul 2006; 15: 2045-2058. Miratul M.K. Muqit, Hum. Mol. Genet., Jan 2004; 13: 117-135. Kenny K. K. Chung, Sci. Aging Knowl. Environ., Apr 2004; 2004: or11. Se Jung Kim, J. Biol. Chem., Oct 2003; 278: 41890-41899.

169790969

NP_004553.2

NM_004562.2

O60260

46,413 Da

Adaptive Immune System Pathway (366160); Alpha-synuclein Signaling Pathway (137913); Antigen Processing: Ubiquitination Proteasome Degradation Pathway (366162); Class I MHC Mediated Antigen Processing Presentation Pathway (366161); Immune System Pathway (106386); Parkin-Ubiquitin Proteasomal System Pathway (700638); Parkinson's Disease Pathway (83098); Parkinsons Disease Pathway (705377); Protein Processing In Endoplasmic Reticulum Pathway (167325); Protein Processing In Endoplasmic Reticulum Pathway (167190)

The precise function of this gene is unknown; however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support. [provided by RefSeq, Jul 2008]

Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, RHOT1/MIRO1, MFN1, MFN2, STUB1, SNCAIP, SEPT5, TOMM20, USP30, ZNF746 and AIMP2 (PubMed:10973942, PubMed:10888878, PubMed:11431533, PubMed:12150907, PubMed:12628165, PubMed:16135753, PubMed:21376232, PubMed:23754282, PubMed:23620051, PubMed:24660806, PubMed:24751536). Mediates monoubiquitination as well as 'Lys-6', 'Lys-11', 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context (PubMed:19229105, PubMed:20889974, PubMed:25621951). Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation (PubMed:17846173, PubMed:19229105). Mediates 'Lys-63'-linked polyubiquitination of a 22 kDa O-linked glycosylated isoform of SNCAIP, possibly playing a role in Lewy-body formation (PubMed:11590439, PubMed:11431533, PubMed:19229105, PubMed:11590439, PubMed:15728840). Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy (PubMed:20889974). Promotes the autophagic degradation of dysfunctional depolarized mitochondria (mitophagy) by promoting the ubiquitination of mitochondrial proteins such as TOMM20, RHOT1/MIRO1 and USP30 (PubMed:19029340, PubMed:19966284, PubMed:23620051, PubMed:24896179, PubMed:25527291). Preferentially assembles 'Lys-6'-, 'Lys-11'- and 'Lys-63'-linked polyubiquitin chains following mitochondrial damage, leading to mitophagy (PubMed:25621951). Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in the regulation of neuron death (PubMed:21376232). Limits the production of reactive oxygen species (ROS). Regulates cyclin-E during neuronal apoptosis. In collaboration with CHPF isoform 2, may enhance cell viability and protect cells from oxidative stress (PubMed:22082830). Independently of its ubiquitin ligase activity, protects from apoptosis by the transcriptional repression of p53/TP53 (PubMed:19801972). May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity (PubMed:11439185). May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. May represent a tumor suppressor gene.

0.1 mg

280 USD